POMDOCTOR LIMITED Announces Full Exercise and Closing of Underwriter's Over-Allotment Option

Rhea-AI Summary

POMDOCTOR (Nasdaq: POM) announced the underwriter fully exercised its over-allotment option to purchase 750,000 ADSs at $4.00 per ADS, with the over-allotment closing on October 10, 2025. Gross proceeds to the company from the Offering, including the prior closing and this exercise, totaled $23,000,016 before underwriting discounts and expenses. The ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker POM. The Offering was conducted on a firm commitment basis, with Joseph Stone Capital acting as underwriter. The SEC declared the company’s Form F-1 effective on September 30, 2025.

Positive

• Gross proceeds of $23,000,016
• Over-allotment exercise of 750,000 ADSs at $4.00
• ADS trading commenced on Nasdaq on October 8, 2025
• Offering completed on a firm commitment basis

Negative

• Gross proceeds reported before underwriting discounts and expenses
• Issuance of 750,000 ADSs increases shares outstanding and dilutes holders

Insights

Capital Markets Analyst

POM completed its IPO over-allotment, raising additional capital and closing the offering on October 10, 2025.

POMDOCTOR LIMITED sold an additional 750,000 ADSs at $4.00 per ADS, bringing gross proceeds to $23,000,016. The transaction follows SEC effectiveness on September 30, 2025 and the ADSs began trading on October 8, 2025 under the ticker POM. The offering closed on October 10, 2025 on a firm commitment basis with Joseph Stone Capital as underwriter.

The business mechanism is straightforward: the underwriter exercised the over-allotment to cover demand, which increased company cash on the balance sheet by the stated gross proceeds before fees. Key dependencies include final net proceeds after underwriting discounts and expenses, and proper use of funds consistent with disclosures. Watch for the final prospectus and SEC filings for exact use-of-proceeds and dilution details over the next quarter; near-term liquidity and reporting updates through the next quarterly filing will show how proceeds are allocated.

GUANGZHOU, China, Oct. 10, 2025 /PRNewswire/ -- POMDOCTOR LIMITED (Nasdaq: POM) (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases in China, today announced the underwriter of its initial public offering (the "Offering") has exercised in full its option to purchase an additional 750,000 American Depositary Shares ("ADSs") at a public offering price of $4.00 per ADS to cover over-allotments. Six ADSs represent one Class A ordinary share, par value US$0.0001 per share, of the Company. Gross proceeds to the Company from the offering, including funds received from the prior closing and exercise of this over-allotment option, totaled $23,000,016, before deducting underwriting discounts and other related expenses. The over-allotment option closing date was October 10, 2025. The ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker symbol "POM."

The Offering was conducted on a firm commitment basis. Joseph Stone Capital, LLC acted as the underwriter for the Offering.

A registration statement on Form F-1 relating to the Offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") (File Number: 333-285771), as amended, and was declared effective by the SEC on September 30, 2025. The Offering was made only by means of a prospectus, forming a part of the effective registration statement. Copies of the final prospectus relating to the Offering, when available, may be obtained from Joseph Stone Capital, LLC by email at corporatefinance@josephstonecapital.com, by standard mail at 585 Stewart Avenue, Unit L60-C, Garden City, NY 11530, or by telephone at +1 888-302-5548. In addition, copies of the final prospectus relating to the Offering, when available, may be obtained via the SEC's website at www.sec.gov.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

 

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-full-exercise-and-closing-of-underwriters-over-allotment-option-302581174.html

SOURCE POMDOCTOR LIMITED

FAQ

How many ADSs did POMDOCTOR sell in the over-allotment exercise?

The underwriter purchased 750,000 ADSs in full as the over-allotment option.

What price per ADS did POMDOCTOR receive for the over-allotment on October 10, 2025?

The over-allotment ADSs were sold at $4.00 per ADS.

How much did POMDOCTOR raise from the Offering including the over-allotment?

Gross proceeds totaled $23,000,016, before underwriting discounts and expenses.

When did POMDOCTOR ADSs begin trading on Nasdaq under the symbol POM?

ADSs began trading on the Nasdaq Global Market on October 8, 2025 under POM.

Who acted as underwriter for POMDOCTOR's IPO and over-allotment?

Joseph Stone Capital, LLC served as the underwriter for the Offering.

Was POMDOCTOR's registration statement declared effective by the SEC?

Yes; the Form F-1 was declared effective by the SEC on September 30, 2025.